Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape

Aruni Ghose; Patricia Lapitan; Vedika Apte; Adheesh Ghosh; Abhinav Kandala; Sreejana Basu; Jo Parkes; Sayali D Shinde; Stergios Boussios; Anand Sharma; Prantik Das; Nikhil Vasdev; Sara E Rebuzzi; Yüksel Ürün; Ravindran Kanesvaran; Akash Maniam; Giuseppe L Banna

doi:10.1007/s11912-024-01524-7

Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape

Curr Oncol Rep. 2024 Apr 23. doi: 10.1007/s11912-024-01524-7. Online ahead of print.

Authors

Aruni Ghose^#^{1

2

3

4

5

6

7

8}, Patricia Lapitan^#^{7

8

9

10

11}, Vedika Apte^#^{12

13}, Adheesh Ghosh¹⁰, Abhinav Kandala¹², Sreejana Basu^{10

13}, Jo Parkes^{5

14

15}, Sayali D Shinde¹⁶, Stergios Boussios^{2

17

18

19

20}, Anand Sharma^{3

4}, Prantik Das^{21

22}, Nikhil Vasdev^{4

23

24}, Sara E Rebuzzi^{6

25

26}, Yüksel Ürün^{27

28}, Ravindran Kanesvaran^{29

30}, Akash Maniam^{31

32

33}, Giuseppe L Banna^{6

34

35}

Affiliations

¹ Department of Medical Oncology, Barts Cancer Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
² Department of Medical Oncology, Medway NHS Foundation Trust, Kent, UK.
³ Department of Medical Oncology, Mount Vernon Cancer Centre, Mount Vernon and Watford NHS Trust, Watford, UK.
⁴ Hertfordshire and Bedfordshire Urological Cancer Centre, Department of Urology, Lister Hospital, East and North Herts NHS Trust, Stevenage, UK.
⁵ Immuno-Oncology Clinical Network, London, UK.
⁶ The Meet-URO Group, Italian Network for Research in Uro-Oncology, Milan, Italy.
⁷ British Oncology Network for Undergraduate Societies, London, UK.
⁸ United Kingdom and Ireland Global Cancer Network, London, UK.
⁹ School of Medical Sciences, University of Manchester, Manchester, UK.
¹⁰ UCL Cancer Institute, University College London, London, UK.
¹¹ Division of Genetics and Epidemiology, Institute of Cancer Research, Surrey, UK.
¹² University College London Medical School, London, UK.
¹³ University College London Oncology Society, London, UK.
¹⁴ Worcestershire Oncology Centre, Worcestershire Acute Hospitals NHS Trust, Worcester, UK.
¹⁵ British Oncology Pharmacy Association, London, UK.
¹⁶ Cancer Academic Sciences Unit, University of Southampton, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
¹⁷ School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK.
¹⁸ Faculty of Medicine, Health and Social Care, Canterbury Christ Church University, Canterbury, UK.
¹⁹ Kent and Medway Medical School, University of Kent, Canterbury, UK.
²⁰ AELIA Organisation, 9Th Km Thessaloniki - Thermi, 57001, Thessaloniki, Greece.
²¹ Department of Oncology, University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK.
²² School of Medicine, University of Nottingham, Nottingham, UK.
²³ School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK.
²⁴ Apollo Hospitals Educational and Research Foundation (AHERF), Chennai, India.
²⁵ Medical Oncology Unit, Ospedale San Paolo, Savona, Italy.
²⁶ Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.
²⁷ Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey.
²⁸ Ankara University Cancer Research Institute, Ankara, Turkey.
²⁹ Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
³⁰ Duke-NUS Medical School, SingHealth Duke-NUS Oncology Academic Clinical Programme, Singapore, Singapore.
³¹ Department of Medical Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK. Akash.Maniam@porthosp.nhs.uk.
³² Faculty of Science and Health, School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK. Akash.Maniam@porthosp.nhs.uk.
³³ Caribbean Cancer Research Institute, Port of Spain, Trinidad and Tobago. Akash.Maniam@porthosp.nhs.uk.
³⁴ Department of Medical Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK.
³⁵ Faculty of Science and Health, School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK.

^# Contributed equally.

PMID: 38652426
DOI: 10.1007/s11912-024-01524-7

Abstract

Purpose of review: Our review delves into the progress across urological malignancies and discusses ongoing challenges and future directions in antibody-drug conjugate (ADC) development, emphasising their transformative potential in cancer care.

Recent findings: ADCs have advanced from hematologic to solid tumours, notably in breast cancer, and are now pivotal in metastatic urological cancers as both monotherapies and in combination regimens, underscored by the FDA's approval of enfortumab vedotin and sacituzumab govitecan for metastatic urothelial cancer. Progress in metastatic prostate cancer, particularly with ADCs targeting PSMA and STEAP1, is noteworthy, although renal cell cancer presents ongoing challenges. There is a continual search for agents in the metastatic, relapsed testicular cancer landscape. ADCs have emerged as a pivotal innovation in oncology, blending targeted antibody therapy with potent cytotoxic drugs, significantly advancing treatment options for urological malignancies.

Keywords: Antibody drug conjugate; Cancer; Chemotherapy; Prostate; Renal; Testicular; Urology; Urothelial.

Publication types

Review